A comprehensive view of Ionis Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca and Ionis' Wainua eplontersen granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis
Published: December 26, 2023 by AstraZeneca AB
La Roche licenses Alzheimer's and Huntington's disease drugs from Ionis Pharma in a deal that gives Roche exclusive worldwide rights to the RNA-targeting medicines; Ionis stands to receive US$60M upfront payment, milestone payments and tiered royalties
Published: September 29, 2023 by Marketline - Deals
Ionis pHARMA expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America; eplontersen is an investigational injectable antisense medicine to treat transthyretin amyloidosis
Published: July 31, 2023 by ENP Newswire

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count